The global cell line development market is anticipated to reach US$ 7.2 billion by 2028, rising at a CAGR of 7.5% over the forecast period (2022-2028), from an estimated US$ 4.7 billion in 2022.

Cell Line Development Market Introduction & Dynamics:

Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.

In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST).

Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period. The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.

Key Market Segments Covered in Cell Line Development Market Study:

By Product Type:

Reagent and Media
Equipment
Accessories and consumables

By Source Type:

Mammalian cell line
Non-mammalian cell line

By End User:

Biopharmaceutical Companies
Contract Research Organizations
Academics and Research Institutes
Biotechnology Companies

By Cell Lines:

Recombinant cell lines
Hybridomas
Continuous cell lines
Primary cell lines

By Region:

North America
Latin America
Europe
CIS & Russia
Japan
APEJ
MEA

Regional Market Analysis:

North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market.

The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.

Key Companies operating in Cell Line Development Market:

Thermo Fischer Scientific, Inc.
GE Healthcare
Merck KGaA
Lonza (Sartorius Stedim Biotech S.A.)
Danaher
Corning Incorporated
WuXi Biologics
Selexis SA
American Type Culture Collection (ATCC)

For More Information: https://www.futuremarketinsights.com/reports/cell-line-development-market